1. Home
  2. KRUS vs QTTB Comparison

KRUS vs QTTB Comparison

Compare KRUS & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kura Sushi USA Inc.

KRUS

Kura Sushi USA Inc.

N/A

Current Price

$34.96

Market Cap

485.4M

ML Signal

N/A

Logo Q32 Bio Inc.

QTTB

Q32 Bio Inc.

N/A

Current Price

$8.91

Market Cap

450.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KRUS
QTTB
Founded
2008
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
485.4M
450.1M
IPO Year
2019
2018

Fundamental Metrics

Financial Performance
Metric
KRUS
QTTB
Price
$34.96
$8.91
Analyst Decision
Buy
Strong Buy
Analyst Count
9
7
Target Price
★ $62.88
$39.67
AVG Volume (30 Days)
193.0K
★ 705.1K
Earning Date
11-05-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
79.75
★ 136.78
EPS
★ N/A
N/A
Revenue
★ $282,763,000.00
$53,737,000.00
Revenue This Year
$16.80
N/A
Revenue Next Year
$17.77
$150.00
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 18.88
N/A
52 Week Low
$29.69
$1.91
52 Week High
$80.84
$23.57

Technical Indicators

Market Signals
Indicator
KRUS
QTTB
Relative Strength Index (RSI) 42.00 47.25
Support Level $33.97 $7.45
Resistance Level $41.99 $9.16
Average True Range (ATR) 1.77 0.53
MACD -0.13 0.25
Stochastic Oscillator 47.71 75.16

Price Performance

Historical Comparison
KRUS
QTTB

About KRUS Kura Sushi USA Inc.

Kura Sushi USA Inc is a technology-enabled Japanese restaurant concept that provides guests with a distinctive dining experience by serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. The company operates a network of dine-in locations across the U.S. states and Washington, DC.

About QTTB Q32 Bio Inc.

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).

Share on Social Networks: